Vasostrict (vasopressin in 5% Dextrose) Injection recall
FDA recall D-0232-2024 · initiated Jan 11, 2024
Par Sterile Products LLC recalled Vasostrict (vasopressin in 5% Dextrose) Injection in Jan 2024 — an FDA Class II recall (D-0232-2024) because Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.
Wrong strength, or it did not keep
The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 1721 cartons
Details
- Product
- Vasostrict (vasopressin in 5% Dextrose) Injection, 20 units per 100 mL (0.2 units per mL), 100 mL x 10 Single Dose Vials per carton, Ready to Use, For Intravenous Infusion, Rx Only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977. NDC: 42023-237-10
- Recalling company
- Par Sterile Products
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- Nationwide USA
- Initiated
- Jan 11, 2024
- FDA report date
- Jan 24, 2024
This recall is linked to a product we cover: Vasostrict →
Frequently asked
- Was Vasostrict (vasopressin in 5% Dextrose) Injection recalled?
- Par Sterile Products LLC recalled Vasostrict (vasopressin in 5% Dextrose) Injection in Jan 2024 — an FDA Class II recall (D-0232-2024) because Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Vasostrict (vasopressin in 5% Dextrose) Injection recalled?
- Per the FDA enforcement record, the reason for recall D-0232-2024 was: Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.
- Is a recalled Vasostrict (vasopressin in 5% Dextrose) Injection dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Vasostrict (vasopressin in 5% Dextrose) Injection are affected?
- Distributed: Nationwide USA. The recall covers these lots — Lot # 66702; Exp. 02/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0232-2024.